Topics
Diffuse midline glioma | Treatment | Clinical trials | CAR-T cells
Home > Publications > Topics > Diffuse midline glioma > Treatment > Clinical trials > CAR-T cells
Majzner
RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM,
Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z,
Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie E,
Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler
E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z,
Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L,
Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G,
Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M.
GD2-CAR
T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature.
2022 Feb 7. doi:
10.1038/s41586-022-04489-4. PMID:
35130560. Interventional study.
ˍ
*Monje
M, Mahdi J, Majzner R, Yeom K, Schultz LM, Richards RM, Barsan V,
Song KW, Kamens J, Baggott C, Kunicki M, Lim AS, Reschke A,
Mavroukakis S, Egeler E, Moon J, Patel S, Chinnasamy H, Erickson
C, Jacobs A, Duh AK, Rietberg SP, Tunuguntla R, Klysz DD, Fowler
C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK, Petersen AG,
McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham K, Bove R,
Musa E, Reynolds W, Kuo A, Prabhu S, Rasmussen L, Cornell TT,
Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye X, Sahaf B,
Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Sequential
intravenous and intracerebroventricular GD2-CAR T-cell therapy for
H3K27M-mutated diffuse midline gliomas.
medRxiv
[Preprint].
2024 Jun 27:2024.06.25.24309146. doi:
10.1101/2024.06.25.24309146. PMID:
38978673. Interventional study. ˍ
Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM,
Barsan V, Song KW, Kamens J, Baggott C, Kunicki M, Rietberg SP,
Lim AS, Reschke A, Mavroukakis S, Egeler E, Moon J, Patel S,
Chinnasamy H, Erickson C, Jacobs A, Duh AK, Tunuguntla R, Klysz
DD, Fowler C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK,
Petersen AG, McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham
K, Bove R, Musa E, Reynolds WD, Kuo A, Prabhu S, Rasmussen L,
Cornell TT, Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye
X, Sahaf B, Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Intravenous and intracranial GD2-CAR T
cells for H3K27M+
diffuse midline gliomas.
Nature.
2024 Nov 13. doi:
10.1038/s41586-024-08171-9. PMID:
39537919. Interventional study.
ˍ
Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea
SD, Beam M, Steinmetzer L, Wilson AL, Brown C, Beebe A, Lindgren
C, Gustafson JA, Wein A, Holtzclaw S, Hoeppner C, Goldstein HE,
Browd SR, Hauptman JS, Lee A, Ojemann JG, Crotty EE, Leary SES,
Perez FA, Wright JN, Alonso MM, Dun MD, Foster JB, Hurst D, Kong
A, Thomsen A, Orentas RJ, Albert CM, Pinto N, Annesley C, Gardner
RA, Ho O, Pattabhi S, Gust J, Wendler JP, Park JR, Jensen MC.
Intracerebroventricular
B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma:
a phase 1 trial.
Nat
Med. 2025 Jan 7. doi:
10.1038/s41591-024-03451-3. PMID:
39775044. Interventional study. ˍ
**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C,
Wen H, Chang LJ, Ma H, Cai Q.
Preliminary
exploration of PSMA CAR-T combined with GD2 CAR-T for the
treatment of refractory/relapsed gliomas.
J
Transl Med. 2025 May 27;23(1):591. doi:
10.1186/s12967-025-06523-1. PMID:
40420236. Interventional study. ˍ